Search

Your search keyword '"Sapacitabine"' showing total 71 results

Search Constraints

Start Over You searched for: Descriptor "Sapacitabine" Remove constraint Descriptor: "Sapacitabine" Topic chemistry Remove constraint Topic: chemistry
71 results on '"Sapacitabine"'

Search Results

1. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

2. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

3. Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

4. A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

5. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations

6. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia

7. The efficacy of sapacitabine in treating patients with acute myeloid leukemia

8. Sapacitabine in acute myelogenous leukemia

9. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

10. An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

11. Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations

12. Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?

13. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

14. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks

15. Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity

16. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types

17. A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells

18. Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy

19. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

20. Outpatient Chemotherapy plus Radiotherapy in Sarcomas: Improving Cancer Control with Radiosensitizing Agents

21. Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

22. Selecting initial treatment of acute myeloid leukaemia in older adults

23. Sapacitabine in the treatment of acute myeloid leukemia

24. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC

25. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

26. Improvement of the antitumor activity of poorly soluble sapacitabine (CS-682) by using Soluplus® as a surfactant

27. Novel drugs for older patients with acute myeloid leukemia

28. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials

29. New agents: great expectations not realized

30. Abstract 4633: The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors

31. Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors

32. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine

33. Sapacitabine for cancer

34. Developing Drugs for Leukemias

35. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

36. Novel agents for the treatment of acute myeloid leukemia in the older patient

37. New nucleoside analogs for patients with hematological malignancies

38. Management of acute myeloid leukemia in older adults

39. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

40. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

41. HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

42. Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology

43. Abstract 2551: Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition

44. Abstract 2549: Tyrosyl-DNA phosphodiesterase 1 (TDP1) is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside antimetabolite in clinical trials targeted to ATM- and BRCA-deficient tumors

45. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies

46. Abstract 5454: Inhibition of Bcr-Abl tyrosine kinase sensitizes cells to sapacitabine

47. Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients

48. A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

49. Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine

50. Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination

Catalog

Books, media, physical & digital resources